FIG. 1



Part 1A Cohort 1, 180 mg QD, Day 1 (N = 5 - 6)
Part 1A Cohort 2, 360 mg QD, Day 1 (N = 3 - 27)
Part 1A Cohort 3, 720 mg QD, Day 1 (N = 11)
Part 1A Cohort 4, 960 mg QD, Day 1 (N = 24 - 25)
Plasma AMG 510 Concentration (ng/mL)
100000
10000
1000
100
0
4
8
12
16
20
24
Time (Hours)

FIG. 2




Part 1A Cohort 1, 180 mg QD, Day 8 (N = 5 - 6)
Part 1A Cohort 2, 360 mg QD, Day 8 (N = 1 - 26)
Part 1A Cohort 3, 720 mg QD, Day 8 (N = 11)
Part 1A Cohort 4, 960 mg QD, Day 8 (N = 23 - 24)
Plasma AMG 510 Concentration (ng/mL)
100000
10000
1000
100
0
4
8
12
16
20
24
Time (Hours)

FIG. 3


Best % Change From Baseline in Sum Diameters
100
50
0
-50
-100
Phase 1 NSCLC 180 mg QD (n=3)
Phase 1 NSCLC 360 mg QD (n=15)
Phase 1 NSCLC 720 mg QD (n=6)
Phase 1 and 2 NSCLC 960 mg QD Fasted & Fed (n = 164)
Treatment Group